John L Reagan

occupation: researcher

official website: vivo.brown.edu/display/jreagan

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 44

Date

Title

Authors

2022-10-15

Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis

Shadi Yaghi, Ian J Saldanha, Chelsea Misquith, Adam de Havenon, Eva A. Mistry, Ekaterina Bakradze, Eric D Goldstein, John L Reagan, Lina Palaiodimou, Karen L Furie, Thalia S Field, Georgios Tsivgoulis, Brian Mac Grory
2020-09-01

Antibiotic use during cytarabine consolidation in acute myeloid leukemia

John L Reagan
2020-09-11

Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based study†

Mengyang Di, Orestis A. Panagiotou, John L Reagan, Adam J. Olszewski
2020-09-11

Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma

Peter Barth, John L Reagan, Adam J. Olszewski
2019-09-30

Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma

Adam J. Olszewski, Peter Barth, John L Reagan
2019-07-09

Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base

Thomas Ollila, John L Reagan, Adam J. Olszewski
2019-12-17

Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma

Adam J. Olszewski, John L Reagan, Jorge Castillo
2018-04-06

Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.

R Shyama Prasad Rao, Nagib Ahsan, Diana Treaba, Adam J. Olszewski, John L Reagan, Olin Liang, Philip A. Gruppuso, Patrycja M Dubielecka
2018-04-24

Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.

Adam J. Olszewski, Thomas Ollila, John L Reagan
2018-03-12

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.

Jorge Castillo, Adam J. Olszewski, John L Reagan, Jose-Tomás Navarro, Michele Bibas
2018

The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia

John L Reagan
2018-09-13

Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis

Nagib Ahsan, Diana Treaba, Adam J. Olszewski, Max Petersen, Christoph Schorl, Xiaoqing Yu, Roberta Zini, Anita Hryniewicz-Jankowska, Elena Oceana, John L Reagan, Olin Liang, Leszek Kotula, Peter J Quesenberry, Philip A. Gruppuso, Rossella Manfredini, Patrycja M Dubielecka
2017-03-28

Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?

John L Reagan
2017-04-06

IgM myeloma: A multicenter retrospective study of 134 patients

Jorge Castillo, Alessandro Gozzetti, John L Reagan, Ivan Špička, Vladimir Maisnar, Hareth Nahi, Angela Dispenzieri, Artur Jurczyszyn, Anna Waszczuk-Gajda, Paul G. Richardson, Ruben Niesvizky, Philippe Moreau, Morie A Gertz, Jacek Czepiel, Jacob P Laubach, Marion Eveillard, Roman Hajek, Ravi Vij, Irene Ghobrial, Vania Hungria, Ludek Pour, Claudia E Paba-Prada, David S Jayabalan, Joshua N Gustine
2017-03-07

Rhomboid glossitis in disseminated CMV infection

John L Reagan
2017-09-29

Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.

Adam J. Olszewski, Jorge Castillo, John L Reagan
2017-11-22

Extracellular vesicles in leukemia.

John L Reagan, Peter J Quesenberry
2016-02-23

Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program

Kalyan Mantripragada, Adam J. Olszewski, John L Reagan
2016-12-01

Hodgkin lymphoma mimicking lung abscess.

John L Reagan
2016-03-22

Acquired Syphilis With Anemia and Leukoerythroblastic Reaction: A Case Report.

Kalyan Mantripragada, John L Reagan
2015-05-02

Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study

Jorge Castillo, Matthew R Sullivan, John L Reagan
2015-12-04

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia

John L Reagan, Kalyan Mantripragada
2015-01-22

Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.

Jorge Castillo, John L Reagan
2014-04-04

Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia

John L Reagan, Adam J. Olszewski
2014-05-02

Differences in the clinical course of heparin induced thrombocytopenia before and after the availability of HIT IgG class testing

John L Reagan
2014-01-01

Advances in cellular therapy for the treatment of leukemia

Kalyan Mantripragada, John L Reagan, Peter J Quesenberry
2014-02-18

Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies

Jorge Castillo, John L Reagan
2014-05-01

Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia

Jorge Castillo, John L Reagan
2014-12-17

Adoptive immunotherapy for myeloid malignancies

John L Reagan
2014-04-10

Primary refractory Hodgkin lymphoma: limited options and poor survival--but not always

John L Reagan, Jorge Castillo
2013-06-19

Cellular immunotherapy for refractory hematological malignancies

John L Reagan, Jorge Castillo, Peter J Quesenberry
2013-08-06

Multiple myeloma-induced hyperammonemic encephalopathy: an entity associated with high in-patient mortality

Jorge Castillo, John L Reagan

Human - wd:Q49487022

Welcome to Inventaire

the library of your friends and communities

learn more